Ru

Investors

Financial results Ratings
Operating profit in 2025
4.9
bln RUB
EBITDA Margin in 2025
24.4%
bln RUB
EBITDA in 2025
9
bln RUB
Revenue in 2025
36.9
bln RUB

Financial results

Detailed information
Consolidated financial statements for 2025 and independent auditor's report
More details
Unaudited condensed interim consolidated financial statements for 6M ended 30 June 2025
More details
Consolidated financial statements for 2024 and independent auditor's report
More details
Consolidated financial statements for 2023 and independent auditor's report
More details
Consolidated financial statements for 2022 and independent auditor's report
More details
Unaudited condensed interim consolidated financial statements for 6M ended 30 June 2021
More details
Combined and consolidated financial statements for 2020 and an independent auditor's report
More details

Ratings

The rating agency assigns credit ratings to Binnopharm Group and ALIUM based on an analysis of the companies strategies, development plans, current debt burden, and financial stability.


Expert RA
ruA
Outlook stable
08/29/2025
Expert RA
ruA
Outlook stable
04/14/2026

In accordance with the Russian law, Binnopharm Group and ALIUM publishes information subject to disclosure by Issuers of Issue-Grade Securities on the website of the security market information provider Interfax-CIDC certified by the Bank of Russia for disclosure purposes. Any information published on this website is for informational purposes only and may not be considered a public offer as defined in Clause 437 of the Russian Civil Code.

Security hotline
Our Security Hotline helps ensure the efficiency of the Company’s measures to combat potential abuse, fraud, corruption, errors and omissions.
You can use the Hotline to report non-performance or improper performance by Binnopharm Group employees of their duties, as well as non-compliance or improper compliance with charters, internal documents, legal requirements, etc. at a time and in a form convenient, including anonymously, by:
emailing to report@binnopharmgroup.ru;
calling +7 800 600 08 24 or +7 495 510 32 88 ext. 3333 and leaving a voice message;
sending a letter marked “personal – SECURITY HOTLINE” Attn.: Internal Audit Director, to the following address: 14 Kozhevnicheskaya St., Bld. 5, 3rd Floor, Moscow, 115114 (Binnopharm Group);
using the feedback form:
File size must not exceed 8 Mb.
    Your reports will be confidentially registered by authorised Binnopharm Group employees for further review and verification. If you are or plan to become a counterparty of Binnopharm Group facilities, and believe that they violate procurement procedures, you can officially contact the Commission for Procurement Disputes at Sistema.
    Подтверждение номера телефона
    Введите код из СМС